CAR-based cellular immunotherapy was initially tested in patients with hematologic malignancies, and CD19 was selected as a preferential target antigen, based on its selective expression on B cells, therefore limiting on-target off-tumor side effects to B-cell aplasia, which may also protect against the risk of developing CAR-directed antibodies. Here, CD19 is linked to neoplasm.